uniQure NV (NASDAQ:QURE) rose 4% during mid-day trading on Friday . The company traded as high as $8.59 and last traded at $8.56, with a volume of 108,140 shares trading hands. The stock had previously closed at $8.23.

QURE has been the topic of a number of recent research reports. Cowen and Company restated a “buy” rating on shares of uniQure NV in a research report on Tuesday, June 14th. Piper Jaffray Cos. reaffirmed a “buy” rating on shares of uniQure NV in a research note on Monday, June 13th. Leerink Swann reaffirmed a “buy” rating on shares of uniQure NV in a research note on Sunday, June 12th. Jefferies Group reaffirmed a “buy” rating on shares of uniQure NV in a research note on Tuesday, May 31st. Finally, Oppenheimer Holdings Inc. reaffirmed a “buy” rating on shares of uniQure NV in a research note on Tuesday, May 31st. One analyst has rated the stock with a sell rating and ten have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $29.10.

The stock’s market cap is $212.95 million. The stock has a 50-day moving average of $7.63 and a 200 day moving average of $11.82.

uniQure NV (NASDAQ:QURE) last posted its quarterly earnings data on Tuesday, May 31st. The company reported ($0.93) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.82) by $0.10. Equities analysts expect that uniQure NV will post ($3.45) EPS for the current year.

Uniqure NV is a pharmaceutical company based in the Netherlands. It is primarily engaged in the field of gene therapy for orphan diseases. The Company is focused on patients suffering from genetic or acquired diseases by directing the expression of a therapeutic protein or restoring the expression of a missing protein through a single administration.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.